本文選題：TNF-α + 拮抗分子　； 參考：《中國人民解放軍軍事醫(yī)學科學院》2005年博士論文

【摘要】：TNF-α的過量表達與很多疾病密切相關,應用TNF-α的拮抗劑部分阻斷這些疾病中的TNF-α水平,將成為一種有效的治療措施。已開發(fā)的TNF-α拮抗劑主要包括兩大類,即TNF受體與IgG的FC段形成的融合蛋白和抗TNF-α的單抗,國外已有成熟產品上市。開發(fā)具有自主知識產權的TNF-α拮抗分子具有重要的理論和實際意義。 本論文擬根據構建的TNF-α與本實驗室獲得的鼠源功能性單抗Z12相互作用的復合物模型合理設計得到的低親和力拮抗肽,借助建立的基于抗原—抗體相互作用結構信息設計抗體模擬物的技術平臺,創(chuàng)造性地提出了三種提高TNF-α拮抗分子生物學活性的技術:(1)將設計的短肽通過Linker與人IgG1的FC段連接后構建成的免疫黏附分子(短肽—Linker-FC);(2)利用人抗體重鏈可變區(qū)(VH)的框架結構作為支架,同時展示三條短肽,設計成新型分子PTVH5;(3)優(yōu)化TNF-α與Z12的復合物模型,設計活性提高的短肽。具體研究結果如下: (1)針對設計的TNF-α拮抗肽(PT1～PT4),選擇抑制TNF-α細胞毒性效果最好的PT4,利用Linker將其與人IgG1的FC段連接,構建成PT4-Linker-FC融合蛋白,提高了PT4熱力學穩(wěn)定性。所構建的融合蛋白能夠競爭抑制HRP標記的Z12與TNF-α的結合,能夠明顯抑制TNF-α介導的細胞毒效應,其抑制活性比單獨的PT4有明顯提高。 (2)考察能否利用人抗體可變區(qū)的框架結構作為支架,同時展示三個活性肽段。選擇已設計的功能肽PT2、PT3和PT4,分別替換人抗體IgG重鏈可變區(qū)的三個CDR區(qū),設計成抑制TNF-α的新型分子(命名為PTVH)。利用同源模建技術從
[Abstract]:The overexpression of TNF- 偽 is closely related to many diseases. The use of TNF- 偽 antagonist to partially block the level of TNF- 偽 in these diseases will be an effective treatment. The developed TNF- 偽 antagonists mainly include two categories: fusion protein formed by FC segment of TNF receptor and IgG and monoclonal antibody against TNF- 偽. It is of great theoretical and practical significance to develop TNF- 偽 antagonist molecules with independent intellectual property rights. In this paper, the low affinity antagonist peptide was designed according to the constructed complex model of TNF- 偽 interacting with mouse functional monoclonal antibody Z12. A technical platform for the design of antibody simulants based on the structure information of antigen-antibody interaction, Three techniques for enhancing the antagonistic molecular biological activity of TNF- 偽 were proposed in this paper: 1) Immunoadhesive molecules (short peptide-Linker-FCX _ 2) using the variable region of heavy chain of human antibody were constructed by connecting the designed short peptide with FC segment of human IgG1 through Linker. The frame structure acts as a scaffold, At the same time, three short peptides were designed to optimize the complex model of TNF- 偽 and Z12, and to design short peptides with improved activity. The specific findings are as follows: 1) for the designed TNF- 偽 antagonist peptide PT1, PT4 was selected to inhibit the cytotoxicity of TNF- 偽. The fusion protein of PT4-Linker-FC was constructed by ligating it with FC segment of human IgG1 by Linker, and the thermodynamics stability of PT4 was improved. The constructed fusion protein could competitively inhibit the binding of HRP labeled Z12 to TNF- 偽 and inhibit the cytotoxic effect mediated by TNF- 偽. The inhibitory activity of the fusion protein was significantly higher than that of PT4 alone. To investigate whether the frame structure of variable region of human antibody can be used as scaffold, and to display three active peptide segments at the same time. The designed functional peptides PT2, PT3 and PT4 were selected to replace the three CDR regions of the heavy chain variable region of human antibody IgG, respectively, and were designed as a novel molecule (named PTVHG) to inhibit TNF- 偽. Using the technology of homologous modeling
【學位授予單位】：中國人民解放軍軍事醫(yī)學科學院
【學位級別】：博士
【學位授予年份】：2005
【分類號】：R392

【相似文獻】

相關期刊論文 前10條

1 馬敏;劉萬林;;TNF-α的表達與激素性股骨頭缺血性壞死關系的研究進展[J];內蒙古醫(yī)學雜志;2011年05期

2 孫設宗;趙杰;官守濤;張紅梅;劉興林;;山藥多糖對CCl_4肝損傷小鼠自由基、TNF-α含量的影響[J];山西醫(yī)科大學學報;2011年06期

3 李安全;王雯;;Barrett食管及反流性食管炎患者血清TNF-α、IL-2水平及意義[J];福建醫(yī)藥雜志;2011年03期

4 甄誠;陳亮;穆蕊;鞏偉麗;柏兆方;王芊藝;滿江紅;;利用Oris技術觀察多種因素對人乳腺癌細胞遷移的影響[J];科學技術與工程;2011年17期

5 張磊;魏偉;;前列腺素E_2與腫瘤壞死因子-α在類風濕性關節(jié)炎中的關系及藥物的調控作用[J];中國臨床藥理學與治療學;2011年08期

6 李小軍;馮純慧;;參附注射液對急性心肌梗死并發(fā)休克患者血清腫瘤壞死因子-α影響的臨床研究[J];貴陽中醫(yī)學院學報;2011年03期

7 高峰;趙欣;史瑞紅;楊小榮;;TNF-α在脊髓背角參與慢性疼痛機制的研究[J];中國醫(yī)療前沿;2011年10期

8 張寶燕;羅碧丹;;小針刀治療頸源性頭痛的療效觀察及機制探討[J];中國針灸;2010年S1期

9 畢s，

本文編號：1940126